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Cerebrospinal fluid dynamics modulation 
by diet and cytokines in rats
Zerin Alimajstorovic1, Ester Pascual‑Baixauli1, Cheryl A. Hawkes1, Basil Sharrack2, A. Jane Loughlin1, 
Ignacio A. Romero1 and Jane E. Preston3* 
Abstract 
Background: Idiopathic intracranial hypertension (IIH) is a neurological disorder characterised by raised cerebrospi‑
nal fluid (CSF) pressure in the absence of any intracranial pathology. IIH mainly affects women with obesity between 
the ages of 15 and 45. Two possible mechanisms that could explain the increased CSF pressure in IIH are excessive 
CSF production by the choroid plexus (CP) epithelium or impaired CSF drainage from the brain. However, the molecu‑
lar mechanisms controlling these mechanisms in IIH remain to be determined.
Methods: In vivo ventriculo‑cisternal perfusion (VCP) and variable rate infusion (VRI) techniques were used to assess 
changes in rates of CSF secretion and resistance to CSF drainage in female and male Wistar rats fed either a control 
(C) or high‑fat (HF) diet (under anaesthesia with 20 μl/100 g medetomidine, 50 μl/100 g ketamine i.p). In addition, CSF 
secretion and drainage were assessed in female rats following treatment with inflammatory mediators known to be 
elevated in the CSF of IIH patients: C–C motif chemokine ligand 2 (CCL2), interleukin (IL)‑17 (IL‑17), IL‑6, IL‑1β, tumour 
necrosis factor‑α (TNF‑α), as well as glucocorticoid hydrocortisone (HC).
Results: Female rats fed the HF diet had greater CSF secretion compared to those on control diet (3.18 ± 0.12 μl/
min HF, 1.49 ± 0.15 μl/min control). Increased CSF secretion was seen in both groups following HC treatment (by 
132% in controls and 114% in HF) but only in control rats following TNF‑α treatment (137% increase). The resistance 
to CSF drainage was not different between control and HF fed female rats (6.13 ± 0.44 mmH2O min/μl controls, and 
7.09 ± 0.26 mmH2O min/μl HF). and when treated with CCL2, both groups displayed an increase in resistance to CSF 
drainage of 141% (controls) and 139% (HF) indicating lower levels of CSF drainage.
Conclusions: Weight loss and therapies targeting HC, TNF‑α and CCL2, whether separately or in combination, may 
be beneficial to modulate rates of CSF secretion and/or resistance to CSF drainage pathways, both factors likely con‑
tributing to the raised intracranial pressure (ICP) observed in female IIH patients with obesity.
Keywords: Idiopathic intracranial hypertension, Ventriculo‑cisternal perfusion, Variable rate infusion, Raised 
intracranial pressure, Cytokines
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Introduction
Idiopathic intracranial hypertension (IIH) is a neuro-
logical disorder characterised by raised intracranial pres-
sure (ICP) and papilloedema in the absence of any other 
intracranial pathology or secondary cause [1, 2]. IIH typi-
cally affects women with obesity between the ages of 15 
and 45, causing disabling daily headaches and visual loss, 
which is severe and permanent in up to 25% of cases [3]. 
While the pathogenesis is not yet known, it is thought 
that raised ICP is caused by an impairment of cerebro-
spinal fluid (CSF) drainage, or an increased production 
of CSF. CSF biomarkers have been used to present an 
insight into the pathogenesis of IIH.
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Various risk factors have been postulated as media-
tors of IIH. Only obesity and female sex have been 
linked with a higher probability of developing the dis-
ease so far, however, it is thought that IIH is a multi-
factorial condition [4]. IIH presents a challenge to 
countries experiencing an obesity epidemic and it is 
thought that the incidence of IIH will increase fol-
lowing the trend in increased rates of obesity that is 
observed globally [5].
Cerebrospinal fluid is a clear fluid that surrounds the 
brain and spinal cord and is produced by the epithelial 
cells of the choroid plexus (CP). The CPs are anatomical 
structures in the third, fourth and lateral ventricles within 
the brain and are formed of blood vessels lined by the cho-
roidal epithelium [6, 7]. The capillary endothelium in the 
CP is fenestrated and surrounded by these epithelial cells, 
joined by tight junctions, all of which constitute the blood–
CSF-barrier (BCSFB) and control CSF composition [8].
It is thought that the main mechanism of CSF secre-
tion is mediated by the CP epithelial cells. In brief, fluid 
secretion by the CP epithelial cells involves the sodium–
potassium ATPase pump  (Na+–K+-ATPase),  Na+–
K+–2Cl− cotransporter (NKCC1), chloride channel 
(CIC-2) and aquaporin-1 water channel (AQP-1) located 
on the apical membrane, driving the efflux of  Na+,  Cl−,  K+, 
 HCO3− and  H2O from the blood into the CSF [6]. Further 
transporters, the chloride–bicarbonate exchanger (AE2) 
and sodium–bicarbonate cotransporters (NCBn1, NCBE), 
located on the basolateral membrane drive the accumula-
tion of  Na+,  Cl− and  HCO3− into the cytoplasm of the CP 
epithelial cells, eventually resulting in CSF secretion [6].
Once secreted, the CSF flows from the lateral and third 
ventricles before exiting through the fourth ventricle and 
into the subarachnoid space (SAS) or spinal cord. There 
are several pathways for CSF drainage but it is thought 
that CSF is predominantly absorbed via the arachnoid 
villi into the dural venous sinuses [9] or the nasal/dural 
lymphatics [10, 11].
The total volume of CSF within adult humans is 
approximately 140  ml and the rate of secretion by each 
CP is 0.2 ml/min [12]. The pressure required for the cir-
culation of CSF is maintained by a hydrostatic pressure 
gradient between the CP (where CSF is produced) and 
the arachnoid villi (where CSF is drained) [8]. The CP 
epithelial cells are indispensable for directed transport 
processes from blood into the CSF, for the removal of 
substances out of the brain, and for CSF production [13].
An underlying inflammatory pathology is present in 
IIH in terms of abnormal expression of inflammatory 
mediators. This is because IIH is strongly associated with 
obesity, a chronic low grade pro-inflammatory state [14].
Cytokines are small, non-structural proteins that are 
synthesized by most nucleated cells. Cytokines include 
interleukins (IL), interferons and colony stimulating factors. 
Cytokines and chemokines (a sub-group of cytokines that 
direct chemotaxis in responsive cells) are involved in regu-
lating inflammatory responses through coordination of cell 
movement to sites of infection [1]. Chemokines facilitate 
the passage of leukocytes from the circulation and into the 
tissues [15]. Due to its links with obesity, IIH may be associ-
ated with increased expression of adipokines and cytokines. 
Inflammatory mediators tumour necrosis factor-α (TNF-
α) [16, 17], IL-6 [18], IL-17 [17] and C–C motif chemokine 
ligand 2 (CCL2) [1] as well as the glucocorticoid cortisol 
(hydrocortisone) [19] were found to be increased in the 
CSF and/or serum of IIH patients. Leptin and IL-1β were 
also studied but showed no significant results in either CSF 
secretion rates or resistance to CSF drainage. Pro-inflam-
matory cytokines could serve as important diagnostic 
markers of molecular pathways that may serve as targets 
for therapeutic intervention [1] if they are found to cause 
elevated ICP and therefore be a cause of IIH.
In addition to obesity being a factor in the incidence of 
IIH, sex hormones may influence patients with IIH as it is 
found to occur mostly in females with obesity.
The overall aim of this study was to investigate the 
effects of weight gain mediated by a high fat diet, and the 
acute effects of inflammatory mediators on CSF dynam-
ics in the rat. In order to do that, CSF secretion in both 
control (C) and high-fat (HF) diet fed male and female 
rat models, and resistance to CSF drainage in female rats, 
with and without cytokine treatment were studied. These 
are the pathways thought to be the main problem caus-
ing increased ICP in IIH patients. HF diet fed female rats 
had the highest rate of CSF secretion. When treated with 
hydrocortisone (HC) and TNF-α, female rats also showed 
increased CSF secretion; as well as decreased CSF drain-
age following CCL2 treatment.
Methods
Animals
All in  vivo techniques were performed at the School of 
Life, Health and Chemical Sciences, The Open Univer-
sity Milton Keynes, UK in accordance with Home Office 
project licence (PPL Number: 70/8507). Male and female 
Wistar rats were ordered Envigo, UK, at 4 weeks of age 
and maintained on either a C pellet or HF diet until sac-
rifice. Rats were fed either a C rodent maintenance 1 diet 
(5.7% fat, 14.4% protein, 79.9% carbohydrate,  Table  1) 
(SDS, Essex, UK) or a HF diet (45% fat, 20%, protein and 
35% carbohydrate,  Table  2) (SDS, Essex, UK). The rats 
were fed ad-libitum and the diets were administered as 
pellets for a period of 7  weeks. Control rats and those 
receiving the HF diet were weighed every week from the 
onset of diet, and rat weights ranged between 250 and 
300 g at the onset of experiments.
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In vivo CSF secretion—the ventriculo‑cisternal perfusion 
technique
The ventriculo-cisternal perfusion (VCP) technique [20] 
was used in anaesthetised rats to measure in  vivo CSF 
secretion rates. Artificial CSF (aCSF: 122  mM NaCl, 
3 mM KCl, 1 mM  CaCl2, 1 mM  MgCl2, 15 mM  NaHCO3, 
15  mM HEPES, 0.5  mM  Na2HPO4, 17.5  mM glucose) 
with 0.5% w/v blue dextran, containing the treatment 
of interest (concentration shown in Table 3) is perfused 
through the lateral ventricles and samples are collected 
over time from the Cisterna magna and analysed by 
spectrophotometry.
The experiment was carried out in 11  week old male 
and female Wistar rats, 250–300  g. The animals were 
first anaesthetised using an isofluorane (Merial Animals 
Health, Essex, UK), administered within an inhalation 
chamber for 5 min. A single intraperitoneal injection of 
‘Domitor’ (medetonidine hydrochloride) at 20  μl/100  g 
weight and ‘Vetalar’ (ketamine) at 50 μl/100 g weight of 
animal (both supplied by the Home Office Named Veteri-
nary Surgeon, Red Kite Veterinary Consultants Centaur 
Services, Castle Cary, UK) was then given.
The head was held in position using a stereotaxic frame 
and a midline cutaneous incision was made from fore-
head to neck to expose the top of the skull. The lateral 
ventricles were located 0.8 mm posterior to the bregma 
and 1.5 mm laterally either side for each lateral ventricle. 
A 0.65  mm hand-chuck drill bit bore holes in the skull 
for insertion of metal cannulae to a depth of 4 mm. The 
cannulae were attached to a water manometer; a fall in 
pressure as the cannulae was inserted confirmed correct 
positioning within the ventricle and a pressure trans-
ducer was then connected to a side arm of the cannula to 
monitor infusion pressure.
A 1 mm diameter needle was inserted into the cisterna 
magna for collection of perfusion outflow. Entry into the 
cisterna magna was obtained by locating the base of the 
occipital bone, found at the back of the rat skull, before 
piercing the arachnoid membrane, below the bone, and 
inserting the needle into the SAS of the cisterna magna. 
Correct positioning of the needle was evident following 
immediate visualisation of aCSF (containing blue dex-
tran) perfusion through the needle and into the 1  mm 
bore tubing.
Two 10  ml plastic syringes (14.5  mm diameter) were 
filled with aCSF containing the treatment/cytokine of 
interest (Table  3). Both lateral ventricles of the brain 
Table 1 Ingredients contained within % (w/w) of SDS RM1 
rodent maintenance C diet
Control diet
Ingredient g% (w/w)
Fat 2.3
Carbohydrates 75.2
Protein 14.4
Fibre 4.7
Minerals 3.3
Vitamins 0.1
Total 100
Table 2 Ingredients contained within % (w/w) of SDS 45% 
AFE HF diet
High‑fat diet
Ingredient g% (w/w)
Fat 38.6
Carbohydrates 30.1
Protein 20.1
Fibre 4.9
Minerals 4.6
Vitamins 1.7
Total 100
Table 3 Concentrations of the treatments added to the aCSF for ventriculo-cisternal perfusion and variable rate infusion 
experiments
Treatment Supplier Dose (ng/ml) Reference based 
on reported levels in CSF 
of IIH patients
Hydrocortisone Sigma‑Aldrich, Dorset, UK (H0135) 500 Sinclair et al. [19]
TNF‑α Sigma‑Aldrich, Dorset, UK (H8916) 0.1 Hayakata et al. [16]
IL‑6 Life Technologies, Paisley, UK (10398‑H08H‑5) 0.1 Reihani‑Kermani et al. [18]
IL‑17 Miltenyi Biotech Ltd, Woking, UK (130‑093‑959) 0.1 Li et al. [41]
CCL2 Cambridge Bioscience, Cambridge, UK (00220‑0‑100) 50 Dhungana et al. [1]
IL‑1β Miltenyi Biotech Ltd, Woking, UK (130‑093‑897) 0.1 Hayakata et al. [16]
Leptin Sigma‑Aldrich, Dorset, UK (L4146) 100 Dhungana et al. [1]
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were perfused using a Harvard slow-drive syringe pump 
(Harvard Apparatus UK, Cambridge, UK, Cat No. 
703007INT) for a total period of time of 90 min. Perfu-
sion inflow rate of aCSF was 20  μl/min for each ventri-
cle for the first 20 min and 10 μl/min for the remaining 
70 min. The choice of perfusion rate was made to remove 
possible clots resulting from cannulae insertion and to 
rapidly flush out endogenous CSF, which was flushed out 
over the first 40  min. The need to reduce clot accumu-
lation was an observation that was determined during 
the initial experiments CSF was sampled from the cis-
terna magna every 10 min to calculate CSF secretion rate 
based on Dextran dilution (ratio of Concentration out/
Concentration in) measured in real time using Fluostar 
Optima, at 625  nm. Once steady-state Dextran dilution 
was achieved (by ≈ 60  min), secretion rates for subse-
quent samples were averaged until the end of the experi-
ment (90  min) to calculate the CSF secretion rate for 
each animal.
The CSF secretion rate was calculated by the dilution 
of the blue dextran as shown in Eq. 1:
where  Cin is the absorbance value of the initial aCSF 
(containing blue dextran) that was perfused into each of 
the lateral ventricles (concentration in) and  Cout is the 
absorbance value of aCSF (containing blue dextran) that 
was perfused out of the cisterna magna (concentration 
out) for a particular perfusion period. The perfusion rate 
was the total of two syringes, i.e 2 × 10 μl/min.
In vivo resistance to CSF drainage—variable rate infusion 
technique
This technique, used by Jones and colleagues measures 
the resistance to absorption of the CSF [21]. As with 
the VCP method, this technique was also carried out in 
female Wistar rats, 250–300 g. The animals were anaes-
thetised before being positioned into the stereotaxic 
frame as described previously.
One 10  ml plastic syringe was placed in the Harvard 
slow-drive syringe pump (Harvard Apparatus UK) (filled 
with aCSF with or without the treatment of interest). 
The concentrations of these treatments were the same as 
those used in VCP experiments, as described in Table 3.
During the variable rate infusion (VRI) technique, per-
fusion of the aCSF with the treatment of interest was 
undertaken through only one lateral ventricle of the brain 
in live anaesthetised rats. The other lateral ventricle was 
inserted with a cannula attached to a pressure transducer 
(Henley’s Medical Ltd, Herts, AL7 1AN UK), and pressure 
(1)
CSF secretion rate (µl/min)
=
Cin − Cout
Cout
× Perfusion rate (µl/min)
readings were taken at 10  min intervals at increasing 
perfusion rates. Infusion of aCSF at a known rate causes 
CSF pressure to rise to a plateau level. The resistance to 
absorption of the CSF was then calculated from the gra-
dient of plateau pressure (recorded over four increasing 
rates), against the infusion rate.
Statistical analysis
All data are presented as mean ± standard deviation of 
the mean and are the result of a number of independent 
experiments (n) with replicates specified in each figure or 
legend. The number of animals used was designed to max-
imise gaining physiologically relevant, statistically significant 
data, whilst minimising the numbers of animals used. We 
focussed on the key group of high fat fed female rats and data 
were gathered to reach statistical significance. This group of 
rats were more homogenous in response compared to con-
trol animals, and data reach statistical significance at n = 3 at 
between P < 0.001 and P < 0.0001 (see Figs. 1, 2, 3 and 4) using 
ANOVA with post hoc testing as described below.
While data from control rats is suggestive of response 
to cytokines in some cases (see Figs. 2 and 4) it did reach 
not reach statistical significance. It could be argued that 
greater numbers might detect significant change, but 
power calculations (https ://www.stat.ubc.ca/~rolli n/stats 
/ssize /n2.html) gave n = 16 rats needed to detect differ-
ences, which was deemed prohibitive for the aims of this 
study. Calculations were performed using GraphPad Prism 
8 software (GraphPad Software, La Jolla, USA). A one-way 
ANOVA was used for comparison of initial control in vivo 
CSF secretion and resistance to CSF drainage experiments 
against treatment groups. A two-way ANOVA was used 
for comparison of in vivo control CSF secretion rates and 
resistance to drainage experiments for both diets, respec-
tively. In all cases, ANOVAs were followed by an unpaired 
t test with Welch-correction (one-way ANOVA) or Sidak’s 
multiple comparison post hoc test (two-way ANOVA) to 
determine a significant difference among groups. The sig-
nificant multiple comparison results following the post-
hoc test is shown in each graph. Positive/negative results 
refer to an increase/decrease in CSF secretion rates over 
controls, respectively. Statistically significant differences 
are presented as probability levels of P < 0.05 (*), P < 0.01 
(**), P < 0.001 (***), P < 0.0001 (****).
Results
Idiopathic intracranial hypertension is a result of raised 
ICP, possibly due to increased CSF secretion, decreased 
drainage, or a combination of both.
CSF secretion
It was important to test diet effects on CSF secretion 
rates in rats fed either C or HF diet due to the increasing 
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incidence of IIH in all populations due to the rising obe-
sity rates and several studies reporting weight gain in 
newly diagnosed IIH patients [22, 23].
Food and water intake are shown in Additional file  1: 
Fig. S1a and b, respectively. The average percentage 
weight gain over the 7-week period was significantly 
higher for the male HF diet rats (447.1%) when compared 
to the C diet (277.7%), as shown in Additional file 1: Fig. 
S2. A smaller but significant increase was observed when 
comparing the HF diet females (347.6%) with C diet 
female rats (265.7%) (Additional file 1: Fig. S3).
Cerebrospinal fluid secretion rates of HF diet females 
(3.18 ± 0.12 μl/min, n = 3) were significantly higher than 
in males fed either the C (1.57 ± 0.23  μl/min, P < 0.001, 
n = 3) or HF diet (2.06 ± 0.42  μl/min, P < 0.01, n = 4), as 
well as compared to females fed the C diet (1.49 ± 0.15 μl/
min,  n = 3, P < 0.0001) (Fig.  1). There was no difference 
between male and female rats when comparing CSF 
secretion rates in animals fed the C diet or between 
males on different diets, which suggests that the influ-
ence of HF diet on CSF secretion was more prominent in 
females (Fig. 1).
Rates of CSF secretion (shown as percentage of con-
trol) were increased in female rats fed both the C 
(131.7% ± 13.1%, n = 3) and HF (113.6% ± 1.3%) diet fol-
lowing HC treatment (Fig.  2). CSF secretion was also 
significantly increased in rats fed the C diet following 
TNF-α treatment (136.5% ± 5.0%, n = 3) (Fig. 2).
Treatment with IL-6, CCL2 and IL-17 did not alter 
rates of CSF secretion in female rats fed either C or HF 
diet (Fig. 2).
Resistance to CSF drainage
The VRI method was used to test the in  vivo effect of 
cytokine treatment on the resistance to CSF drainage 
over four increasing infusion rates (5, 10, 16, 20  μl/
min). The resistance to CSF drainage was compared in 
Fig. 1 Control CSF secretion rates in male and female rats fed either a C or HF diet. Each VCP experiment was carried out by perfusing aCSF 
through both lateral ventricles of the rat brain. CSF secretion rates for a males and b females were calculated from the dilution of Blue Dextran (Blue 
Dextran  Cout/Cin) after steady‑state was reached shown by the lines (solid line control, dashed line high fat diet HF). c Samples from male C (n = 3), 
male HF (n = 4), female C (n = 3), female HF (n = 3) rats were averaged (±SD) and compared to one another. A two‑way ANOVA was used to analyse 
the statistical significance. The significant results are shown following Sidak’s multiple comparison test a two‑tailed equal variance t‑test comparison 
each diet and sex variable. **P = ≤ 0.01, ***P = ≤ 0.001, ****P = ≤ 0.0001. aCSF artificial cerebrospinal fluid, C control diet, HF high‑fat diet, VCP 
ventriculo‑cisternal perfusion
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untreated female animals on C and HF diets (Fig.  3). 
The results showed no significant differences between 
female rats fed a HF diet (7.1 ± 0.3  mmH2O  min/
μl, n = 3) and females fed the C diet (6.1 ± 0.4 
 mmH2O  min/μl, n = 3). We therefore decided to test 
the effect of cytokines on resistance to CSF drainage on 
female rats raised on either a C or HF diet.
Treatment of rats fed a C diet with TNF-α and 
HC induced a decrease in resistance to CSF drain-
age compared to untreated rats (40.8% ± 39.7% and 
62.5% ± 42.6%, n = 3 respectively), however this decrease 
did not reach statistical significance (Fig. 4).
There were no significant changes in resistance to 
CSF drainage in female rats fed either a C or HF diet 
following IL-6 or IL-17 treatment (Fig.  4). However, 
CCL2 induced a significant increase in females fed the 
C diet (140.6% ± 7.5%,  n = 3, P < 0.001) and HF diet 
(138.9 ± 3.4%, n = 3, P < 0.0001) over the respective con-
trols (Fig. 4).
Discussion
In the current study, we provide an in  vivo insight into 
potential mechanisms relating to the pathogenesis of IIH. 
We highlight increased CSF secretion rates in female rats 
fed a HF diet as well as following cytokine treatment in 
both diets (HC) and C diet (TNF-α). We also describe an 
increase in resistance to CSF drainage following CCL2 
treatment in female rats on both diets, all of which pro-
vide a pathogenic link between weight gain and increased 
ICP in IIH.
Fig. 2 Effect of cytokine treatment on CSF secretion rate in female rats fed a C or HF diet. CSF secretion rates for a female controls and b female 
HF diet rats, were calculated from the dilution of Blue Dextran (Blue Dextran  Cout/Cin) after steady‑state was reached shown by the lines (solid lines 
no cytokines, dashed lines with cytokine). c CSF secretion rates were then calculated as a percentage change from each respective control (±SD) 
from female C (n = 3) and female HF (n = 3) rats for each respective cytokine treatment (n = 3). A two‑way ANOVA was used to analyse the statistical 
significance. The significant results are shown following Sidak’s multiple comparison test a two‑tailed equal variance t‑test comparison each diet 
and sex variable. *P = ≤ 0.05, ***P=≤ 0.001. aCSF artificial cerebrospinal fluid, C control diet, HF high‑fat diet, VCP ventriculo‑cisternal perfusion, HC 
hydrocortisone, TNF-α tumour necrosis factor‑α, IL-6 interleukin‑6, IL-17 interleukin‑17, CCL2 C–C motif chemokine ligand‑2
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CSF secretion
The biggest increase in CSF secretion rates was seen in 
female rats fed on a HF diet regardless of treatment used.
The increased CSF secretion rates associated with HC 
may be consistent with the hypothesis that an increased 
activity of the 11β-HSD1 enzyme in CP epithelial cells 
leads to increased  Na+ transport through the ENaC [19]. 
Indeed, HC increases the activity of the ENaC in retinal 
pigment epithelium of New Zealand White Albino rab-
bits [19] and it is possible that a similar mechanism oper-
ates in CP epithelium where three isoforms of ENaC have 
been detected [24]. In this putative pathway, corticoster-
one would be converted to cortisol through NADP(H) 
activation of the 11β-HSD1 enzyme in CP epithelium. 
The enzyme has been identified in CP and preferentially 
generates cortisol through oxo-reductase activity [19]. 
Sinclair et  al. propose that cortisol would then bind to 
intracellular glucocorticoid receptors, activating serum 
glucocorticoid kinase 1 pathways to increase the move-
ment of  Na+ across the cells via ENaC route, creating an 
osmotic gradient in order to drive water into the CSF. 
The cellular location of ENaC and its involvement in  Na+ 
and water movement across the CP epithelium has yet to 
be established however. For example, if the channel is on 
the basal (blood) face, it could facilitate  Na+ movement 
into the epithelium, supporting  Na+/K+ ATPase medi-
ated  Na+ flux to CSF, but it is difficult to see how that 
can be accomplished if ENaC is on the apical (CSF) face 
as suggested [19]. The 11β-HSD1 pathway, which may 
modulate CSF secretion rate, may also be induced by 
TNF-α. TNF-α up-regulates 11β-HSD1 enzyme through 
the secretion of phospholipase A2 in rat glomerular 
mesangial cells [25]. The joint perfusion of TNF-α and 
HC in the aCSF for example could be useful to investigate 
whether an additive effect of these treatments could be 
seen on CSF secretion rates.
Based on the results, the increased levels of cortisol in 
HF diet groups may mediate, at least partly, the increase 
in CSF secretion rates in rats fed a HF diet over rats 
raised on C diets within this study. Of the other inflam-
matory mediators tested, IL-6, IL-17 and CCL2, no 
changes were seen to CSF secretion in either control or 
HF rats. This does not of course, rule out other factors 
induced by a HF diet that may influence CSF dynamics 
in IIH patients with obesity. However, our results here 
suggest a collective treatment against HC elevation, pos-
sibly through inhibition of 11B-HSD1 activity, and a low-
fat diet could be the main course of therapy for reducing 
raised ICP associated with female IIH patients with obe-
sity following future studies.
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Fig. 3 Control resistance to CSF drainage values in female rats fed a 
C or HF diet. Each VRI experiment was carried out by perfusing aCSF 
with each treatment through one lateral ventricle of the rat brain. 
Samples from each group were averaged (±SD); female C (n=3), 
female HF (n=3) and compared to one another. The graph shows 
the averaged resistance to CSF drainage readings  (mmH2O min/μl). A 
one‑way ANOVA was used to analyse the statistical significance. The 
significant results are shown following Sidak’s multiple comparison 
test and was performed against each diet. aCSF artificial cerebrospinal 
fluid, C control diet, HF high‑fat diet, VRI variable rate infusion
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Fig. 4 Resistance to CSF drainage values in female rats fed a C or HF 
diet with cytokine treatment. Each VRI experiment was carried out 
by perfusing aCSF with each treatment through one lateral ventricle 
of the rat brain. Values were calculated as a percentage change from 
each respective control from female C (n = 3) and female HF (n = 3) 
rats for each respective cytokine treatment (n = 3). The graph shows 
the averaged resistance to CSF drainage readings  (mmH2O min/μl) 
as a percentage change from control. A two‑way ANOVA was used to 
analyse the statistical significance. The significant results are shown 
following Sidak’s multiple comparison test and was performed for 
each diet and treatment variable. ***P = ≤ 0.001, ****P = ≤ 0.0001. 
aCSF artificial cerebrospinal fluid, C control diet, HF high‑fat diet, VRI 
variable rate infusion, HC hydrocortisone, TNF-α tumour necrosis 
factor‑α, IL-6 interleukin‑6, IL-17 interleukin‑17, CCL2 C–C motif 
chemokine ligand‑2
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In addition to obesity being a factor in the incidence of 
IIH, sex hormones may influence patients with IIH as it 
is found to occur mostly in premenopausal women with 
obesity [26], with a female to male ratio of 8:1 [1].
Endocrinological dysfunction within females of child-
bearing age have been postulated as causes of increased 
ICP in female IIH patients [27]. Increased amounts of 
adipose tissue, also associated with obesity, acts as an 
endocrine organ, releasing hormones such as leptin, and 
produces increased levels of oestrogen via the conver-
sion of androstenedione. This can lead to physiologically 
abnormal amounts of these hormones in a person’s body 
which may contribute to the development of IIH [27, 28] 
or symptoms of IIH [29]. There is evidence of increased 
oestrogen and prolactin hormone levels giving rise to 
cortisol and TNF-α, respectively, in females [30]. Female 
rats have a more intense corticosterone response to stress 
effect, (partially mediated by oestrogen) [31] which could 
offer a potential mechanism by which increased CSF 
secretion is more likely to be associated with female rats 
over males.
TNF-α is also elevated in healthy control subjects of 
human females over males [32]. Women generate high 
serum levels of anterior pituitary hormone prolactin, in 
response to stressful stimuli [30]. Prolactin is known to 
stimulate the immune system, enhancing proliferation and 
function of lymphocytes and macrophages which are cells 
that can secrete cytokines. Studies by Zhu have shown 
TNF-α plasma level increases following subcutaneous 
injection of prolactin in male mice [30]. This could be the 
reason why the CSF secretion rates on C diet female rats 
with TNF-α treatment were elevated in our study.
Treating elevated CSF secretion in IIH patients may be 
achieved through either serotonin to inhibit  Na+–K+-
ATPase pathway through the activation and phosphoryla-
tion of protein kinase C [33]; antisense thyroid transcription 
factor-1 oligodeoxynucleotide to reduce AQP1 mRNA and 
protein expression in the CP [34]; or acetazolamide and 
topiramate treatment [35] to decrease intracellular car-
bonic anhydrase CP epithelium [6]. However, reducing 
weight loss and inhibiting the actions of reproductive hor-
mones as well as HC and may result in decreased CSF for-
mation and ICP in IIH patients.
Resistance to CSF drainage
A HF diet did not change resistance to CSF drainage. 
However, in terms of additional cytokine treatment 
CCL2 caused increased resistance in the both female 
groups. Overall, CCL2 in female rats fed a HF diet had 
the biggest impact on resistance to CSF drainage in vivo, 
possibly through this increased arachnoid resistance to 
CSF outflow. Obesity is an inflammatory condition where 
increased circulating or CSF cytokines may result in 
fibrotic changes or lead to a hypercoagulable state caus-
ing blockage of the arachnoid villi and, therefore reducing 
drainage of CSF [36]. This pathway is also often aggra-
vated by thrombophilic exogenous oestrogens. In addi-
tion, further studies on the associations between CCL2 
on inflammation of the arachnoid villi, hyperandrogen-
ism and PCOS, may highlight a possible role in the cause 
of increased resistance to CSF drainage and elevated ICP 
in female IIH patients with obesity [37–39].
Decreases in resistance to CSF drainage were seen 
in the female rats fed a C diet following HC and TNF-α 
treatment (although not significant), which was not 
seen in the HF diet female group. Studies have shown 
an increase in the expression of AQP4 in the glymphatic 
pathway, due to the release of TNF-α, during parenchy-
mal CSF absorption [40]. This may explain the tendency 
to decreasing resistance to CSF drainage associated with 
TNF-α in rats fed on a C diet. Whether this mechanism 
is altered in rats on a HF diet remains to be determined.
Overall, pro-inflammatory cytokines, especially CCL2, 
could potentially be used as diagnostic markers and may 
serve as targets for therapeutic intervention following 
further studies in larger cohorts. This being if they are 
found to alter CSF drainage pathways; cause elevated ICP 
through increased resistance to CSF drainage; and there-
fore contribute to IIH. Developing an inhibitory treat-
ment against CCL2 elevation in patients with IIH could 
be advantageous in reducing this resistance of CSF drain-
age, possibly around the arachnoid granulations, and 
therefore lowering ICP.
Conclusion
Weight loss and therapies targeting HC, TNF-α and 
CCL2, whether separately or in combination, may be 
beneficial to modulate rates of CSF secretion and/or 
resistance to CSF drainage pathways, both factors likely 
contributing to the raised ICP observed in female IIH 
patients with obesity.
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rats fed a C or HF diet. Graphs for food (a) and water (b) intake of male and 
female rats raised on either a C or HF diet are displayed. Figure S2. Aver‑
age percentage weight gain of male rats fed a C or HF diet over a 7‑week 
period. Readings were recorded weekly over a 7‑week period (from 4 
weeks of age) for both C and HF diet male rats. Average percentage 
weight gain was monitored prior to VCP and VRI experiments which were 
performed at 11 weeks of age. Figure S3. Average percentage weight 
gain of female rats fed a C or HF diet over a 7‑week period. Readings were 
recorded weekly over a 7‑week period (from 4 weeks of age) for HF diet 
rats and four week period (from 7 weeks of age) for C diet rats (extrapo‑
lated over literature female rat weights at week 0 (red line)). Average 
percentage weight gain was monitored prior to VCP and VRI experiments 
which were performed at 11 weeks of age.
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